c2 8

C2-8 is an inhibitor of polyglutamine (polyQ) aggregation with IC50s of 25 and 0.05 μM for recombinant HDQ51 and in PC12 cells, respectively. It also limits polyQ aggregation in organotypic hippocampal slice cultures from R6/2 transgenic mice and reduces neurodegeneration dose-dependently in a Drosophila model of Huntington's disease. C2-8 (100 and 200 mg/kg) decreases huntingtin aggregate size, reduces neuronal atrophy, and enhances motor performance in a rotarod test in the R6/2 transgenic mouse model of Huntington's disease.

TLR7/8 agonist 12-PAB-(PEG4-Me)-Cit-Val-PEG2-amide-C2-MC (compound LIV1-IMC (12) linker-payload) serves as a linker-payload conjugate designed for the synthesis of antibody-drug conjugates (ADCs). This structure incorporates a TLR7/8 agonist (ADC payload) along with a linker.

Palbociclib (PD 0332991) is a CDK inhibitor that inhibits CDK4 and CDK6 (IC50=11/16 nM) and is orally active. Palbociclib has anti-tumorigenic activity and has investigational potential for use in ER-positive and HER2-negative breast cancer.

Cbz-NH-PEG8-C2-acid is a PEG-based linker for PROTACs that joins two essential ligands, facilitating selective protein degradation via the ubiquitin-proteasome system within cells.

Mal-amido-PEG8-C2-acid (US2018339985, example 142) is a noncleavable linker for antibody-drug conjugates (ADCs) [1].

Pomalidomide-PEG3-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.

Pomalidomide-PEG4-C2-NH2 (E3 Ligase Ligand-Linker Conjugates 22) is a synthesized E3 ligase ligand-linker conjugate incorporating the Pomalidomide-based cereblon ligand and 4-unit PEG linker.

Pomalidomide-C2-Br is a conjugate of an E3 ligase ligand and a linker. It is used in the synthesis of PROTACAR Degrader-8.